The PPAR-γ activators TZDs (pioglitazone and rosiglitazone) are approved by the FDA for type 2 diabetes [165], but are thought to exert beneficial effects on SARDs with altered PPAR-γ activity [160]. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.